GDF15 and hepatocellular carcinoma: Interim data from a phase 2a study of visugromab, anti-GDF15 mAb, plus nivolumab in patients with advanced stage, anti-PD-(L)1 relapsed/refractory solid tumors (non-small cell lung cancer, urothelial cancer, HCC) showed an ORR among the 16 HCC patients of 18.8%, with two achieving partial response and one complete response [78] (Table 2).